Can Medtronic Buy Its Way to Growth? It Sure Thinks So.

Even earlier Medtronic (NYSE:MDT) announced its fiscal fourth-quarter 2026 earnings, the institution was telling Wall Street it was starting down a caller path. That's a bully thing, due to the fact that the aged way wasn't making investors happy, noting that the banal has fallen much than 40% from its 2021 high.

A large portion of Medtronic's maturation program is apt to impact acquisitions, specified arsenic the already-completed woody for Cathworks and the pending acquisition of SPR Therapeutics. Here's what investors request to cognize astir this aesculapian instrumentality elephantine and its charismatic 3.8% yield.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

Image source: Getty Images.

Medtronic has plentifulness of "firepower"

At an manufacture league earlier successful the year, Medtronic's CFO explained that the institution has the balance-sheet capableness to marque acquisitions if it wants to. And with 2 deals already successful the books successful 2026, 1 completed and the different inactive pending, the institution is intelligibly putting its words into action.

However, it is important to callback however the institution got to this point. Essentially, the ample and diversified aesculapian instrumentality concern had go bloated and inefficient implicit time. That led to dilatory maturation and less-than-inspiring earnings. It took immoderate clip to revamp the business, a process that included selling assets, divesting businesses (most notably the spin-off of the company's diabetes business), and streamlining operations.

The extremity effect is simply a much focused institution that tin present thin into growth. The program appears to beryllium working, with the company’s fiscal 2026 gross maturation coming successful astatine the fastest gait successful a decade. Organic maturation was 5.8%.

Something notable here, however, is that Medtronic did each of this portion continuing to enactment its dividend policy. It is present conscionable 2 years distant from Dividend King status, with 48 yearly increases nether its loop contempt a large concern overhaul. CFO Thierry Pieton made definite to item that information astatine the manufacture conference. That the dividend is intelligibly a constituent of pridefulness for Medtronic should beryllium precise pleasing to dividend investors, fixed its well-above-market yield. The institution announced different summation erstwhile it reported its fiscal 2026 earnings, putting it connected way to deed 49 consecutive years.

Medtronic is getting backmost to maturation

That said, the bigger communicative is that Medtronic is returning to growth. One important improvement is the company's Hugo surgical robot, which is present being utilized successful the United States. This highlights that the healthcare institution remains arsenic innovative arsenic ever. However, acquisitions are besides an important portion of the maturation plan.